Haynes, Barton F.

Changes in thymic function with age and during the treatment of HIV infection

Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan#, J. L., et al. (1998) · Nature

HIV Research and TreatmentT-cell and B-cell Immunology

Cited by 1,893

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature

Mosquito-borne diseases and controlRNA Interference and Gene Delivery

Cited by 884

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature

HIV Research and TreatmentCarbohydrate Chemistry and Synthesis

Cited by 830

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 530

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 378

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 324

Prospects for a safe COVID-19 vaccine

Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 261

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 253

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01

Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S. D., McKee, K., Louder, M. K., Ledgerwood, J. E., et al. (2011) · Journal of Virology

HIV Research and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 235

Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion

Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases

HIV Research and TreatmentRNA Interference and Gene Delivery

Cited by 181

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., et al. (2019) · Molecular Therapy - Nucleic Acids

HIV Research and TreatmentSARS-CoV-2 and COVID-19 Research

Cited by 103

Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes

Kapingidza, B., Marston, D. J., Harris, C., Wrapp, D., Winters, K., Mielke, D., Xiaozhi, L., Yin, Q., Foulger, A., Parks, R., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 26

Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide

Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., Kunz, E. L., Zhang, R., Vandergrift, N., Permar, S., et al. (2014) · Journal of Virology

HIV Research and TreatmentCarbohydrate Chemistry and Synthesis

Cited by 18